ESMO 2023 | Future directions of targeted agents in the treatment of thyroid and neuroendocrine tumors

Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses the therapies available for differentiated thyroid and endocrine tumors, and the trials currently exploring novel treatment options for these cancer subsets. Dr Grande elaborates on the use of RET inhibitors to treat patients in the Phase III LIBRETTO-531 (NCT04211337) trial, as well as the use of atezolizumab and cabozantinib in the Phase II CABATEN (NCT04400474) trial. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.